BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10328843)

  • 1. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
    Belloli C; Crescenzo G; Carli S; Zaghini A; Mengozzi G; Bertini S; Ormas P
    Vet J; 1999 May; 157(3):315-21. PubMed ID: 10328843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.
    Belloli C; Ceci L; Carli S; Tassi P; Montesissa C; De Natale G; Marcotrigiano G; Ormas P
    Res Vet Sci; 1995 Mar; 58(2):123-7. PubMed ID: 7761689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
    Valladares JE; Alberola J; Esteban M; Arboix M
    Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
    Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
    J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
    Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
    Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
    Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
    Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
    Chulay JD; Fleckenstein L; Smith DH
    Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial.
    Athanasiou LV; Saridomichelakis MN; Kontos VI; Spanakos G; Rallis TS
    Vet Parasitol; 2013 Feb; 192(1-3):91-7. PubMed ID: 23140991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: A randomized, blinded, controlled study.
    Kasabalis D; Chatzis MK; Apostolidis K; Xenoulis PG; Buono A; Petanides T; Leontides LS; Polizopoulou ZS; Steiner JM; Suchodolski JS; Saridomichelakis MN
    Exp Parasitol; 2019 Nov; 206():107768. PubMed ID: 31539540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
    Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
    Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of liposome-encapsulated antimony in dogs.
    Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
    Braz J Med Biol Res; 2003 Feb; 36(2):269-72. PubMed ID: 12563530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of aminosidine after repeated administrations using an optimal dose regimen in healthy dogs and in dogs with leishmaniosis.
    Athanasiou LV; Batzias GC; Saridomichelakis MN; Delis G; Soubasis N; Kontos VI; Rallis TS
    Vet Parasitol; 2014 Sep; 205(1-2):365-70. PubMed ID: 24998095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania infantum.
    Kasabalis D; Chatzis MK; Apostolidis K; Petanides T; Athanasiou LV; Xenoulis PG; Mataragka A; Ikonomopoulos J; Leontides LS; Saridomichelakis MN
    Exp Parasitol; 2020 Jul; 214():107903. PubMed ID: 32360142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
    Valladares JE; Freixas J; Alberola J; Franquelo C; Cristofol C; Arboix M
    Am J Trop Med Hyg; 1997 Oct; 57(4):403-6. PubMed ID: 9347953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
    Saridomichelakis MN; Xenoulis PG; Chatzis MK; Kasabalis D; Steiner JM; Suchodolski JS; Petanides T
    Vet Parasitol; 2013 Oct; 197(1-2):22-8. PubMed ID: 23685064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters.
    Alnaim L; Abou Alsoud N; Zaghloul I; Al-Jaser M
    Int J Antimicrob Agents; 2007 Jun; 29(6):728-32. PubMed ID: 17369029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.
    Miekeley N; Mortari SR; Schubach AO
    Anal Bioanal Chem; 2002 Feb; 372(3):495-502. PubMed ID: 11939540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate.
    Ikeda-Garcia FA; Lopes RS; Marques FJ; de Lima VM; Morinishi CK; Bonello FL; Zanette MF; Perri SH; Feitosa MM
    Vet Parasitol; 2007 Feb; 143(3-4):254-9. PubMed ID: 16996214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.